AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: ...

AbbVie ABBV announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...

Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose . SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" ...

Each cell in our body experiences up to tens of thousands of DNA-damaging events per day, primarily from routine cellular ...

AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult ...

Oncologists caution that at-home genetic tests taken up by millions of Americans looking to gauge their cancer risk are not ...

Gynaecological cancers are tumours located in the female reproductive system, and they include ovarian, uterine (or endometrial), cervical, vulval and vaginal cancer.

In the PRIMA trial, Zejula (niraparib) improved progression-free survival when used as a maintenance therapy in women with ovarian cancer after chemotherapy. Crucially for GSK, the study also ...

Veteran broadcaster Alan Jones has been charged with historical indecent assault and sexual touching offences spanning two decades.